COVID-19：日本のファビピラビル,中国臨床試験：コロナ治療に効果的(海外各紙）:
Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials：
在中国临床试验中，日本流感药物在冠状病毒治疗中似乎“有效”
COVID-19：日本のファビピラビル
日本製のインフルエンザ薬ファビピラビルは、製品名Aviganとして知られています。
患者のCOVID-19ウイルス/持続期間短縮に､効果的であることが示されました。
インフルエンザ薬ファビピラビルで治療した場合、肺の状態が、大幅に改善したとのこと。
中国の医療当局：
武漢とShenzhenで､罹患患者を対象に実施した臨床試験の結果を発表しました。
China science and technology ministry:
The trials involved 340 patients in total, and since they drug has already been developed and
approved for use in treating flu, it has a “high degree of safety,”
according to China science and technology ministry official
Zhang Xinmin, who spoke to reporters on Wednesday according to The Guardian.
The tests:
showed a reduction in the period during which patients tested positive for the new coronavirus from 11 days down to just four,
and showed improvements in the lung condition of around 91 percent of patients treated with favipiravir, compared to just 62 percent for those without among the trial participants.
The Chinese studies are not the only attempt to test the efficacy of the drug in COVID-19 treatment – Japanese doctors are bonding their own studies.
A Japanese health ministry source:
told Japanese newspaper the Manichi Shimbun that the drug so far has been given to around 70 to 80 people, but that early results suggest it isn’t effective in treating those with more severe symptoms where the virus has already multiplied to a much greater extend.
Still, a treatment that is effective in reducing the duration of the presence of the virus even in milder cases, and in lessening the impacts in moderate symptomatic patients,
would be a huge benefit to the ongoing fight against the coronavirus.
Any approvals for use of favipiravir would of course require further clinical testing, followed by approval of widespread use by each country’s relevant medical treatment regulating body.
TechCrunch